Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA.
Adolescent
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ blood
Carcinoma, Hepatocellular
/ blood
Circulating Tumor DNA
/ blood
Clinical Decision-Making
/ methods
Cohort Studies
DNA Mutational Analysis
Female
Gene Frequency
Genetic Testing
/ methods
High-Throughput Nucleotide Sequencing
Humans
Liver Neoplasms
/ blood
Male
Middle Aged
Mutation
Patient Selection
Prognosis
United States
Young Adult
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 10 2019
15 10 2019
Historique:
received:
12
10
2018
revised:
15
02
2019
accepted:
25
07
2019
pubmed:
1
8
2019
medline:
22
9
2020
entrez:
1
8
2019
Statut:
ppublish
Résumé
Molecular profiling has been used to select patients for targeted therapy and determine prognosis. Noninvasive strategies are critical to hepatocellular carcinoma (HCC) given the challenge of obtaining liver tissue biopsies. We analyzed blood samples from 206 patients with HCC using comprehensive genomic testing (Guardant Health) of circulating tumor DNA (ctDNA). A total of 153/206 (74.3%) were men; median age, 62 years (range, 18-91 years). A total of 181/206 patients had ≥1 alteration. The total number of alterations was 680 (nonunique); median number of alterations/patient was three (range, 1-13); median mutant allele frequency (% cfDNA), 0.49% (range, 0.06%-55.03%). This study represents the first large-scale analysis of blood-derived ctDNA in HCC in United States. The genomic distinction based on HCC risk factors and the high percentage of potentially actionable genomic alterations suggests potential clinical utility for this technology.
Identifiants
pubmed: 31363003
pii: 1078-0432.CCR-18-3341
doi: 10.1158/1078-0432.CCR-18-3341
pmc: PMC9292132
mid: NIHMS1536269
doi:
Substances chimiques
Biomarkers, Tumor
0
Circulating Tumor DNA
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6107-6118Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA186566
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA190945
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000371
Pays : United States
Organisme : NCI NIH HHS
ID : K07 CA106458
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA180964
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA170035
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA178744
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Cancer Res. 2015 Apr 1;75(7):1187-90
pubmed: 25672981
Hepatology. 2018 Aug;68(2):723-750
pubmed: 29624699
PLoS One. 2015 Oct 16;10(10):e0140712
pubmed: 26474073
Cancer Cell. 2014 Feb 10;25(2):152-65
pubmed: 24525232
Mol Cancer. 2017 Aug 30;16(1):149
pubmed: 28854942
Clin Cancer Res. 2016 Nov 15;22(22):5497-5505
pubmed: 27185373
J Clin Oncol. 2009 Apr 20;27(12):2091-6
pubmed: 19188670
Nature. 2012 Jun 28;486(7404):532-6
pubmed: 22722830
Nat Genet. 2015 May;47(5):505-511
pubmed: 25822088
Clin Chim Acta. 2001 Nov;313(1-2):139-42
pubmed: 11694251
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
Invest New Drugs. 2013 Oct;31(5):1367-74
pubmed: 23591629
Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3110-5
pubmed: 24520177
Cancer Treat Rev. 2009 May;35(3):262-71
pubmed: 19117687
Hepatology. 2013 Nov;58(5):1693-702
pubmed: 23728943
Oncotarget. 2016 Oct 25;7(43):69267-69275
pubmed: 27661004
Gastroenterology. 2017 Mar;152(4):880-894.e6
pubmed: 27939373
J Cancer Res Clin Oncol. 2006 Jun;132(6):399-407
pubmed: 16502316
Cell Mol Gastroenterol Hepatol. 2015 Jun 17;1(5):516-534
pubmed: 28210698
Cell. 2014 Aug 14;158(4):929-944
pubmed: 25109877
Br J Cancer. 2007 Nov 19;97(10):1399-403
pubmed: 17940509
Oncotarget. 2016 Aug 23;7(34):54253-54262
pubmed: 27276713
Oncotarget. 2015 Nov 24;6(37):40360-9
pubmed: 26452027
Cancer Res. 2017 Oct 1;77(19):5419-5427
pubmed: 28807936
Cell Biosci. 2016 May 11;6:32
pubmed: 27182434
Oncologist. 2018 May;23(5):586-593
pubmed: 29487225
Cancer Treat Rev. 2011 May;37(3):221-33
pubmed: 20817364
Nat Genet. 2012 May 06;44(6):694-8
pubmed: 22561517
J Natl Cancer Inst. 2015 Apr 11;107(7):
pubmed: 25863335
Gastroenterology. 2013 Jul;145(1):176-187
pubmed: 23567350
Cancer Discov. 2014 Jun;4(6):650-61
pubmed: 24801577
Ann Oncol. 2016 Mar;27(3):539-43
pubmed: 26646755
Cancer Discov. 2015 Oct;5(10):1040-8
pubmed: 26109333
Cell. 2017 Jun 15;169(7):1327-1341.e23
pubmed: 28622513
Nat Genet. 2014 Dec;46(12):1267-73
pubmed: 25362482
Clin Cancer Res. 2019 Apr 1;25(7):2116-2126
pubmed: 30373752
Gastroenterology. 2013 May;144(5):888-902
pubmed: 23485860
Oncotarget. 2013 May;4(5):705-14
pubmed: 23670029
Ann N Y Acad Sci. 2000 Apr;906:8-12
pubmed: 10818587
Hepatology. 2005 Nov;42(5):1208-36
pubmed: 16250051
Nat Med. 2008 Sep;14(9):985-90
pubmed: 18670422